Preoperative Chemoradiation for Locally Advanced Rectal Cancer: Comparison of Three Radiation Dose and Fractionation Schedules

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2016 Jun 17

PMID 27306773

Citations 4

Authors

Shin-Hyung Park

Jae-Chul Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: The standard radiation dose for patients with locally rectal cancer treated with preoperative chemoradiotherapy is 45-50 Gy in 25-28 fractions. We aimed to assess whether a difference exists within this dose fractionation range.

Materials And Methods: A retrospective analysis was performed to compare three dose fractionation schedules. Patients received 50 Gy in 25 fractions (group A), 50.4 Gy in 28 fractions (group B), or 45 Gy in 25 fractions (group C) to the whole pelvis, as well as concurrent 5-fluorouracil. Radical resection was scheduled for 8 weeks after concurrent chemoradiotherapy.

Results: Between September 2010 and August 2013, 175 patients were treated with preoperative chemoradiotherapy at our institution. Among those patients, 154 were eligible for analysis (55, 50, and 49 patients in groups A, B, and C, respectively). After the median follow-up period of 29 months (range, 5 to 48 months), no differences were found between the 3 groups regarding pathologic complete remission rate, tumor regression grade, treatment-related toxicity, 2-year locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival, or overall survival. The circumferential resection margin width was a prognostic factor for 2-year locoregional recurrence-free survival, whereas ypN category was associated with distant metastasis-free survival, disease-free survival, and overall survival. High tumor regression grading score was correlated with 2-year distant metastasis-free survival and disease-free survival in univariate analysis.

Conclusion: Three different radiation dose fractionation schedules, within the dose range recommended by the National Comprehensive Cancer Network, had no impact on pathologic tumor regression and early clinical outcome for locally advanced rectal cancer.

Citing Articles

Dosimetric impact of variable air cavity within PTV for rectum cancer.

Chan E, Goodall S, Finnegan R, Moorfoot P, Jameson M, Dunn L J Appl Clin Med Phys. 2024; 26(1):e14539.

PMID: 39361507 PMC: 11714072. DOI: 10.1002/acm2.14539.

Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer.

Lee S, Jwa E, Kim D, Kim T, Baek J, Cha Y Int J Clin Oncol. 2018; 23(5):924-929.

PMID: 29774483 DOI: 10.1007/s10147-018-1293-4.

Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base.

Jhaveri J, Rayfield L, Liu Y, Chowdhary M, Cassidy R, Madden N J Gastrointest Oncol. 2018; 8(6):998-1008.

PMID: 29299360 PMC: 5750186. DOI: 10.21037/jgo.2017.10.05.

Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer.

Bae B, Kang M, Kim J, Kim M, Choi G, Kim J Radiat Oncol J. 2017; 35(3):208-216.

PMID: 29037023 PMC: 5647757. DOI: 10.3857/roj.2017.00353.

Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis.

Jeong S, Nam T, Jeong J, Kim S, Kim K, Jang H Clin Exp Metastasis. 2016; 33(8):809-816.

PMID: 27553616 DOI: 10.1007/s10585-016-9818-6.

References

Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R . Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008; 72(1):99-107. DOI: 10.1016/j.ijrobp.2007.12.019. View

Arruda Viani G, Stefano E, Soares F, Afonso S . Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression. Int J Radiat Oncol Biol Phys. 2010; 80(4):985-91. DOI: 10.1016/j.ijrobp.2010.03.008. View

Arbman G, Nilsson E, Hallbook O, Sjodahl R . Local recurrence following total mesorectal excision for rectal cancer. Br J Surg. 1996; 83(3):375-9. DOI: 10.1002/bjs.1800830326. View

Kapiteijn E, Marijnen C, Nagtegaal I, Putter H, Steup W, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345(9):638-46. DOI: 10.1056/NEJMoa010580. View

Wibe A, Rendedal P, Svensson E, Norstein J, Eide T, Myrvold H . Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002; 89(3):327-34. DOI: 10.1046/j.0007-1323.2001.02024.x. View

Glynne-Jones R, Mawdsley S, Pearce T, Buyse M . Alternative clinical end points in rectal cancer--are we getting closer?. Ann Oncol. 2006; 17(8):1239-48. DOI: 10.1093/annonc/mdl173. View

Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D . Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31):3827-33. DOI: 10.1200/JCO.2012.42.9597. View

Sanghera P, Wong D, McConkey C, Geh J, Hartley A . Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol). 2008; 20(2):176-83. DOI: 10.1016/j.clon.2007.11.013. View

Sebag-Montefiore D, Stephens R, Steele R, Monson J, Grieve R, Khanna S . Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009; 373(9666):811-20. PMC: 2668947. DOI: 10.1016/S0140-6736(09)60484-0. View

10.

Chan A, Wong A, Langevin J, Jenken D, Heine J, Buie D . Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys. 2000; 48(3):843-56. DOI: 10.1016/s0360-3016(00)00692-1. View

11.

Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen S . Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys. 2012; 84(4):949-54. DOI: 10.1016/j.ijrobp.2012.02.006. View

12.

Wiltshire K, Ward I, Swallow C, Oza A, Cummings B, Pond G . Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2005; 64(3):709-16. DOI: 10.1016/j.ijrobp.2005.08.012. View

13.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C . Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014; 32(15):1554-62. DOI: 10.1200/JCO.2013.54.3769. View

14.

van Gijn W, Marijnen C, Nagtegaal I, Meershoek-Klein Kranenbarg E, Putter H, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12(6):575-82. DOI: 10.1016/S1470-2045(11)70097-3. View

15.

Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12(1):19-23. DOI: 10.1007/s003840050072. View

16.

Nagtegaal I, Marijnen C, Kranenbarg E, van de Velde C, van Krieken J . Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002; 26(3):350-7. DOI: 10.1097/00000478-200203000-00009. View

17.

Appelt A, Ploen J, Vogelius I, Bentzen S, Jakobsen A . Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2012; 85(1):74-80. PMC: 3539741. DOI: 10.1016/j.ijrobp.2012.05.017. View

18.

Bujko K, Nowacki M, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M . Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10):1215-23. DOI: 10.1002/bjs.5506. View

19.

Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J . Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009; 373(9666):821-8. PMC: 2668948. DOI: 10.1016/S0140-6736(09)60485-2. View

20.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View